完全缓解率（BVAS=0+0 mg GC+无复发）：Benralizumab组23.5% vs 11.1%(p=0.02) 安全性特征：两组不良事件发生率相似; 机制探索发现，Benralizumab通过直接结合IL-5受体(IL-5R)诱导抗体依赖性细胞介导的细胞毒性(ADCC)，可在给药后24小时内将外周血嗜酸性粒细胞降至不可检测水平。

Benralizumab是一款与嗜酸性粒细胞表面表达的IL-5Rα相结合的单克隆抗体。 通过与IL-5Rα相结合，它能够募集天然杀伤细胞，通过诱发嗜酸性粒细胞的 ...

据悉，Benralizumab最初由协和麒麟开发，2006年12月，MedImmune与其达成协议，获得benralizumab在美国、欧洲和其它国家的商业化权益。

SHAMAL研究在重症哮喘治疗方面取得了重大突破。它表明，生物疗法benralizumab使患者能够显著减少或停止使用高剂量吸入类固醇，这是众所周知的严重副作用。通过最大限度地降低与类固醇使用相关的风险，这可能标志着在管理影响全球近3亿人的严重哮喘方面迈出了革命性的一步。

Benralizumab is noninferior to mepolizumab in achieving remission of relapsing or refractory eosinophilic granulomatosis with polyangiitis at 36 and 48 weeks, according to data published in The ...

A new treatment for asthma attacks is being described as “game-changing” by the London scientists who created it. The drug, which is called benralizumab, is the first new treatment for asthma ...

Benralizumab, an anti–interleukin-5 receptor alpha monoclonal antibody, was significantly better than placebo at producing a histologic response of up to six eosinophils per high-power field ...

Treatment with benralizumab induced histological remission, defined as an absence of tissue eosinophilia, among patients with eosinophilic gastritis, according to a study published in The Lancet ...

Learn about side effects, uses, dosage, and more for Fasenra (benralizumab), a prescription drug that treats eosinophilic asthma in adults and some children.

Benralizumab generic Benralizumab is a type of monoclonal antibody which is prescribed as an add-on maintenance treatment for treating severe eosinophilic asthma in patients 12 years of age and older.